Immunome (IMNM): Biotech minnow in the spotlight as volatility returns to cancer drug hunters

Immunome’s stock has seen recent volatility as investors weigh its antibody discovery platform and oncology pipeline against valuation concerns. Despite recent swings, the stock has shown an overall upward trend over the past year, rewarding patient investors. Wall Street analysts largely hold a “Buy” or “Outperform” consensus, anticipating significant upside based on clinical and strategic milestones, although some advocate for a “Hold” due to early-stage assets and inherent development risks.